Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022
The Pure-Vu system improved the adequate cleansing rate more than 200% to 97.7% in patients with a history of poor bowel preparation
FORT LAUDERDALE, Fla., May 24, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today positive topline data from an investigator initiated EU study that show the Pure-Vu system provides adequate cleaning in patients with a history of poor bowel preparation. These data were presented in a poster during Digestive Disease Week 2022.
